Aurobindo Pharma Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For AUROPHARMA, that strike is ₹1,640. Spot at ₹1,653.1 is near max pain — the expiry magnetic pull is active.
Max Pain Level
The current max‑pain strike for Aurobindo Pharma Limited (AUROPHARMA) sits at ₹1,640. This is the price at which the aggregate loss of option writers (both call and put sellers) would be minimized, so market forces often gravitate the underlying toward this level as expiry approaches.
Spot vs Max Pain Gap
The market price is trading at ₹1,653.1, a modest +0.8 % premium over the max‑pain level. The positive gap suggests a slight upward bias, yet the proximity to the pain point means the spot could be pulled back as option‑related hedging activity intensifies.
Shift Signal
The max‑pain figure shows no shift from yesterday, indicating a stable equilibrium for option writers. A stagnant pain level typically reflects that the majority of open interest remains concentrated around the same strike, reinforcing the current magnet effect without introducing new directional pressure.
Expiry Context
Max pain is derived from the net open‑interest of all strikes, weighted by the payoff structure of calls and puts; as expiration nears, market makers will hedge to force the underlying toward the strike that limits their overall loss. Historically, during the final week of an Indian equity options expiry, the underlying often oscillates around the pain point, but this remains a statistical tendency rather than a deterministic outcome.
Data Note
With 25 days left to the September 29 expiry, the spot sits ₹13.1 above the max‑pain level of ₹1,640, a narrow cushion that could be tested by the usual expiry‑week dynamics.
Data as of 2026-09-04